| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Stuart Smith | Q38359925 |
| P2093 | author name string | Richard Grundy | |
| Ruman Rahman | |||
| Cheryl Rahman | |||
| P2860 | cites work | Inhibition of human malignant glioma growth in vivo by human recombinant plasminogen kringles 1-3. | Q48154100 |
| Expression of fibroblast growth factor receptor-1 in human glioma and meningioma tissues | Q48180366 | ||
| ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis. | Q48228816 | ||
| Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants | Q48346110 | ||
| Angiostatin suppresses malignant glioma growth in vivo | Q48366983 | ||
| Influence of surfactants, polymer and doxorubicin loading on the anti-tumour effect of poly(butyl cyanoacrylate) nanoparticles in a rat glioma model | Q48419354 | ||
| Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival | Q48422988 | ||
| Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945. | Q48438372 | ||
| Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. | Q48445523 | ||
| Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier | Q48520343 | ||
| Fibroblast growth factor receptor (FGFR) 4 correlated with the malignancy of human astrocytomas | Q48629133 | ||
| Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. | Q48789795 | ||
| Tumor angiogenesis: a quantitative method for histologic grading | Q48800177 | ||
| Drug resistance-associated factors in primary and secondary glioblastomas and their precursor tumors | Q48944020 | ||
| Continuous delivery of endogenous inhibitors from poly(lactic-co-glycolic acid) polymeric microspheres inhibits glioma tumor growth | Q49066494 | ||
| Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns. | Q51393527 | ||
| Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis. | Q52539830 | ||
| Heat shock protein expression in human gliomas. | Q53710715 | ||
| Expression and localization of 92 kDa type IV collagenase/gelatinase B (MMP-9) in human gliomas. | Q55480149 | ||
| Angiogenesis | Q56689455 | ||
| The thrombospondins | Q57919794 | ||
| Modulation of serine proteinases and metalloproteinases during morphogenic glial-endothelial interactions | Q71071865 | ||
| Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms | Q71656434 | ||
| Brain tumors in children | Q72827847 | ||
| Polymeric systems for controlled drug release | Q77367258 | ||
| Hypoxia-inducible factor 1: master regulator of O2 homeostasis | Q77485489 | ||
| High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor | Q81159672 | ||
| Three weeks release BCNU loaded hydrophilic-PLGA microspheres for interstitial chemotherapy: Development and activity against human glioblastoma cells | Q81599352 | ||
| MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia | Q21092263 | ||
| Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation | Q22004269 | ||
| Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins | Q24299560 | ||
| VEGF-Trap: a VEGF blocker with potent antitumor effects | Q24535043 | ||
| Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme | Q24555728 | ||
| Modes of resistance to anti-angiogenic therapy | Q24608005 | ||
| Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis | Q24608039 | ||
| Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis | Q24610450 | ||
| The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors | Q24629817 | ||
| miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells | Q24649056 | ||
| Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas | Q24649857 | ||
| Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model | Q24655262 | ||
| Comprehensive genomic characterization defines human glioblastoma genes and core pathways | Q24656128 | ||
| The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis | Q24656947 | ||
| The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo | Q24657924 | ||
| The role of pericytes in blood-vessel formation and maintenance | Q24683881 | ||
| The 2007 WHO classification of tumours of the central nervous system | Q24685772 | ||
| Silencing of microRNAs in vivo with 'antagomirs' | Q27860891 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression | Q28138812 | ||
| CD36: a critical anti-angiogenic receptor | Q28205179 | ||
| Exploiting tumour hypoxia in cancer treatment | Q28264146 | ||
| microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma | Q28280337 | ||
| Expression of hypoxia-inducible factor 1? in brain tumors | Q29540607 | ||
| Small molecule inhibitors in children with malignant gliomas | Q37478343 | ||
| Tumour angiogenesis: its mechanism and therapeutic implications in malignant gliomas | Q37531434 | ||
| Biology of angiogenesis and invasion in glioma | Q37533625 | ||
| Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications | Q37553909 | ||
| Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan | Q37594926 | ||
| Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy | Q37597158 | ||
| Primary postoperative chemotherapy without radiotherapy for treatment of brain tumours other than ependymoma in children under 3 years: results of the first UKCCSG/SIOP CNS 9204 trial | Q37612212 | ||
| MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. | Q38353056 | ||
| Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters | Q39799499 | ||
| Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy | Q39830942 | ||
| microRNA-146b inhibits glioma cell migration and invasion by targeting MMPs. | Q39876302 | ||
| Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma | Q39887954 | ||
| Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells | Q40234354 | ||
| Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic | Q40396835 | ||
| Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. | Q40469450 | ||
| Apicidin is a histone deacetylase inhibitor with anti-invasive and anti-angiogenic potentials | Q40585662 | ||
| Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment | Q40662071 | ||
| Glioma invasion in the central nervous system | Q41131785 | ||
| Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. | Q41151821 | ||
| Integrins, angiogenesis and vascular cell survival | Q41239257 | ||
| Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. | Q41481649 | ||
| Tumor necrosis factor activates human endothelial cells through the p55 tumor necrosis factor receptor but the p75 receptor contributes to activation at low tumor necrosis factor concentration | Q42108713 | ||
| Different angiogenic phenotypes in primary and secondary glioblastomas | Q42803768 | ||
| Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. | Q42805196 | ||
| Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. | Q43283510 | ||
| Macrophage activation for the production of immunostimulatory cytokines by delivering interleukin 1 via biodegradable microspheres | Q43799795 | ||
| Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling | Q43873079 | ||
| BCNU-loaded poly(D, L-lactide-co-glycolide) wafer and antitumor activity against XF-498 human CNS tumor cells in vitro | Q44277733 | ||
| Release kinetics of 5-fluorouracil-loaded microspheres on an experimental rat glioma | Q44393384 | ||
| Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. | Q44393459 | ||
| Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas | Q44477258 | ||
| Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451. | Q45261337 | ||
| VEGF gene therapy: stimulating angiogenesis or angioma-genesis? | Q45871293 | ||
| The hypoxic response of tumors is dependent on their microenvironment. | Q45965473 | ||
| Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. | Q45975157 | ||
| Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. | Q46129562 | ||
| A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). | Q46239069 | ||
| Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. | Q46294074 | ||
| Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience | Q46476922 | ||
| A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme | Q46566505 | ||
| Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study | Q46585156 | ||
| Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias | Q46634561 | ||
| The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts | Q46652649 | ||
| Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells | Q46738605 | ||
| A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer | Q46800161 | ||
| Bevacizumab plus irinotecan in recurrent glioblastoma multiforme | Q46942082 | ||
| Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles | Q48003121 | ||
| Emerging functions of microRNAs in glioblastoma | Q37439491 | ||
| A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme | Q37451156 | ||
| Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis | Q29614537 | ||
| Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor | Q29617062 | ||
| Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) | Q29620605 | ||
| MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes | Q30434616 | ||
| Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults | Q30439565 | ||
| AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. | Q30490422 | ||
| A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients | Q30493217 | ||
| Angiogenesis in gliomas: imaging and experimental therapeutics | Q31028310 | ||
| Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence | Q31148416 | ||
| A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study | Q33376981 | ||
| Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma | Q33382596 | ||
| Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study | Q33383828 | ||
| A phase I trial of enzastaurin in patients with recurrent gliomas | Q33384375 | ||
| The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype | Q33674720 | ||
| Biodegradation and biocompatibility of PLA and PLGA microspheres | Q33933142 | ||
| Nanoparticulate systems for brain delivery of drugs | Q33938252 | ||
| Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery | Q33955046 | ||
| New methods for direct delivery of chemotherapy for treating brain tumors. | Q34007625 | ||
| Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta. | Q34102569 | ||
| VEGF in brain tumors | Q34178821 | ||
| The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery | Q34218914 | ||
| Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. | Q34340836 | ||
| Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results | Q34372107 | ||
| Vasculogenesis | Q34387300 | ||
| Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer | Q34389542 | ||
| Pulsed controlled-released system for potential use in vaccine delivery | Q34393996 | ||
| Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice | Q34432972 | ||
| Pharmacokinetics of the carmustine implant | Q34696172 | ||
| MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells. | Q34819445 | ||
| MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells | Q34842477 | ||
| Local drug delivery to the brain | Q34971435 | ||
| Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption | Q34997337 | ||
| Up-regulation of angiopoietin-2, matrix metalloprotease-2, membrane type 1 metalloprotease, and laminin 5 gamma 2 correlates with the invasiveness of human glioma | Q35083735 | ||
| HIF hydroxylation and the mammalian oxygen-sensing pathway | Q35086143 | ||
| Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report | Q35799962 | ||
| Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. | Q35943388 | ||
| Can tumor angiogenesis be inhibited without resistance? | Q35992864 | ||
| Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma | Q36013325 | ||
| Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype | Q36013331 | ||
| Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. | Q36132447 | ||
| VEGF as a therapeutic target in cancer | Q36319029 | ||
| Integrins and angiogenesis: a sticky business | Q36330257 | ||
| The role of angiopoietins during angiogenesis in gliomas | Q36359226 | ||
| The role of the extracellular matrix in angiogenesis in malignant glioma tumors | Q36359232 | ||
| Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). | Q36610166 | ||
| A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse | Q36621800 | ||
| Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas | Q36860502 | ||
| Angiogenesis in brain tumours | Q36887534 | ||
| Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas | Q36900428 | ||
| Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma | Q36926772 | ||
| Integrins: molecular determinants of glioma invasion | Q36978429 | ||
| Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme | Q37036939 | ||
| Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma. | Q37069238 | ||
| HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion | Q37098976 | ||
| Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma | Q37104779 | ||
| New molecular targets in angiogenic vessels of glioblastoma tumours | Q37106536 | ||
| Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study | Q37121681 | ||
| Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies | Q37141964 | ||
| The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases | Q37165851 | ||
| Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma | Q37214249 | ||
| Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells | Q37221453 | ||
| MicroRNAs in development and disease | Q37247281 | ||
| Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease | Q37284331 | ||
| VEGF Trap induces antiglioma effect at different stages of disease | Q37284357 | ||
| Novel anti-angiogenic therapies for malignant gliomas | Q37325086 | ||
| Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab | Q37395361 | ||
| PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival | Q37407269 | ||
| Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors | Q37416895 | ||
| The role of microRNAs in synaptic development and function | Q37428165 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | angiogenesis inhibitor | Q574834 |
| P304 | page(s) | 251231 | |
| P577 | publication date | 2010-04-11 | |
| P1433 | published in | Journal of oncology | Q26853876 |
| P1476 | title | Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma | |
| P478 | volume | 2010 |
| Q37993772 | Activation of alternative pathways of angiogenesis and involvement of stem cells following anti-angiogenesis treatment in glioma |
| Q38264310 | Antiangiogenic therapies for glioblastoma |
| Q30737224 | Antiangiogenic therapy of brain tumors: the role of bevacizumab. |
| Q46118866 | Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. |
| Q36390700 | Bone marrow derived myeloid cells orchestrate antiangiogenic resistance in glioblastoma through coordinated molecular networks |
| Q24616631 | Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition |
| Q36041205 | CD105 (Endoglin) exerts prognostic effects via its role in the microvascular niche of paediatric high grade glioma. |
| Q38763117 | Cancer Therapeutics Following Newton's Third Law |
| Q36684023 | Combination of vatalanib and a 20-HETE synthesis inhibitor results in decreased tumor growth in an animal model of human glioma |
| Q34662536 | Combined efficacy of cediranib and quinacrine in glioma is enhanced by hypoxia and causally linked to autophagic vacuole accumulation |
| Q39313430 | D-Amino acid oxidase-induced oxidative stress, 3-bromopyruvate and citrate inhibit angiogenesis, exhibiting potent anticancer effects |
| Q38967004 | Direct effect of bevacizumab on glioblastoma cell lines in vitro |
| Q30514025 | EphB2 receptor controls proliferation/migration dichotomy of glioblastoma by interacting with focal adhesion kinase |
| Q42572336 | Evaluation of Endoglin as an Angiogenesis Marker in Glioblastoma. |
| Q42835218 | Glioma cells enhance angiogenesis and inhibit endothelial cell apoptosis through the release of exosomes that contain long non-coding RNA CCAT2. |
| Q47899134 | Glioma progression through the prism of heat shock protein mediated extracellular matrix remodeling and epithelial to mesenchymal transition. |
| Q48479445 | Hypoxia in Gliomas: Opening Therapeutical Opportunities Using a Mathematical-Based Approach |
| Q41883885 | Hypoxic cell waves around necrotic cores in glioblastoma: a biomathematical model and its therapeutic implications. |
| Q34701587 | Immunotherapy of brain cancers: the past, the present, and future directions |
| Q47122277 | Impact of Blood Vessel Quantity and Vascular Expression of CD133 and ICAM-1 on Survival of Glioblastoma Patients. |
| Q92799574 | Interleukin-8 Secreted by Glioblastoma Cells Induces Microvascular Hyperpermeability Through NO Signaling Involving S-Nitrosylation of VE-Cadherin and p120 in Endothelial Cells |
| Q47773621 | Major Challenges and Potential Microenvironment-Targeted Therapies in Glioblastoma. |
| Q39205018 | Nuclear magnetic resonance imaging of tumour growth and neovasculature performance in vivo reveals Grb7 as a novel antiangiogenic target. |
| Q38738395 | PVT1 affects growth of glioma microvascular endothelial cells by negatively regulating miR-186. |
| Q35161323 | Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects |
| Q37312695 | Quinacrine synergistically enhances the antivascular and antitumor efficacy of cediranib in intracranial mouse glioma |
| Q47192935 | Radiogenomic analysis of hypoxia pathway is predictive of overall survival in Glioblastoma |
| Q39248369 | Regulatory effects of Spirulina complex polysaccharides on growth of murine RSV-M glioma cells through Toll-like receptor 4. |
| Q35758314 | Surgical delivery of drug releasing poly(lactic-co-glycolic acid)/poly(ethylene glycol) paste with in vivo effects against glioblastoma |
| Q39506220 | Survivin promotes glioma angiogenesis through vascular endothelial growth factor and basic fibroblast growth factor in vitro and in vivo. |
| Q35863135 | Synergistic Antivascular and Antitumor Efficacy with Combined Cediranib and SC6889 in Intracranial Mouse Glioma |
| Q38906010 | The Different Effects of VEGFA121 and VEGFA165 on Regulating Angiogenesis Depend on Phosphorylation Sites of VEGFR2. |
| Q48681774 | The Hedgehog signalling pathway and its prognostic impact in human gliomas |
| Q37124552 | The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma |
| Q38033241 | Therapeutic targeting of VEGF in the treatment of glioblastoma |
| Q42288158 | Toxicological effects of NCKU-21, a phenanthrene derivative, on cell growth and migration of A549 and CL1-5 human lung adenocarcinoma cells. |
| Q41857963 | VEGFR-2 Expression in Glioblastoma Multiforme Depends on Inflammatory Tumor Microenvironment. |
| Q33868524 | Vascular Mimicry: A Novel Neovascularization Mechanism Driving Anti-Angiogenic Therapy (AAT) Resistance in Glioblastoma |
| Q39691814 | Vascular Mimicry: The Next Big Glioblastoma Target |
| Q52369050 | circ-SHKBP1 Regulates the Angiogenesis of U87 Glioma-Exposed Endothelial Cells through miR-544a/FOXP1 and miR-379/FOXP2 Pathways. |
Search more.